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Appraisal Correspondence
Response to Bjordal et al
We thank Professor Bjordal and colleagues from the World 
Association for Laser Therapy (WALT) for their interest in 
our systematic review on interventions for neck pain (Leaver 
et al 2010). Professor Bjordal identiﬁed two material errors 
that occurred in the data extraction phase of our study that 
hide a signiﬁcant beneﬁt for laser therapy for disability at 
medium-term follow-up. An erratum item in this issue of 
Journal of Physiotherapy (p. 222) explains the source of 
these errors and corrects the meta-anaylsis accordingly. 
Our re-analysis indicates that laser therapy is more effective 
than placebo in terms of pain and disability outcomes at 
medium term follow-up, but not at the conclusion of a 
course of treatment.
Our analysis of medium term disability included two trials 
by the same author (Chow et al 2004, Chow et al 2006) and 
incorrectly applied exclusion criteria to a third trial (Gur et 
al 2004). The included trials both used the same disability 
outcome measure, however used a different scale for each 
study and this was not apparent in the published article. 
This explains the ‘good’ effect that Professor Bjordal 
obtained with analysis of the standardised mean difference 
between laser and placebo for disability at medium term. 
This ﬁnding is consistent with our re-analysis, in which the 
disability outcomes from the trial by Chow et al (2006) were 
converted to percentage scores, according to our review 
protocol. This reanalysis of weighted mean difference 
demonstrates a ‘good’ effect for laser therapy on disability 
at medium term (WMD –10, 95% CI –15 to –6).
Professor Bjordal raises additional methodological issues 
with our review that can be clariﬁed. Concerns about the 
inclusion of data from a crossover trial (Thorsen et al 1992) 
without a sufﬁcient washout period are unwarranted because 
data from time points after the crossover period were not 
used. Only the outcomes reported at the conclusion of the 
course of treatment, which was the period immediately 
before crossover, were included in the analysis. Second, 
there was no anomaly in the pain outcomes extracted from 
the trial by Gur et al (2004). These data were extracted at 
Week 2, which was the conclusion of the course of treatment 
as speciﬁed by our review protocol.
The reasons for variability in pain and disability outcomes 
across the trials were not easily explained by our review and 
we suggested that a more detailed review of laser therapy 
might shed further light on this question. Professor Bjordal 
and colleagues have since conducted this review (Chow et 
al 2009) and have suggested that variability in outcomes 
between trials is related to a dose-response phenomenon. 
This pattern was not apparent in our review. On the contrary, 
there were examples of trials that used dosage parameters 
consistent with WALT guidelines that demonstrated no 
effect (Dundar et al 2007: 830nm, 7J per point) as well as 
trials that used doses Professor Bjordal would describe as 
‘very low’ (Ozdemir et al 2001: 830nm, 0.9 J per point) 
that reported very large treatment effects. Additionally, the 
WALT guidelines suggest that the number of points treated 
is a signiﬁcant dosage parameter. There was very large 
variation, both between and within the trials reviewed, 
of the number of points treated (Range 4–50) and hence 
the total energy delivered during the treatment. The other 
explanation offered by Professor Bjordal for the variability 
in outcomes was that the therapeutic effect of laser therapy 
is characteristically delayed. This phenomenon also was not 
apparent in our review. Any conclusions about the size of 
the treatment effect over time were difﬁcult to draw because 
few trials reported both short- and medium-term outcomes, 
and those that did had mixed results regarding immediate 
and delayed effects. We found evidence in some studies of 
an immediate analgesic effect and in others an apparent 
delayed effect and we are not aware of any biologically 
plausible explanation for this ﬁnding.
Although not directly related to the discussion on laser 
therapy, Professor Bjordal also commented on the need 
to balance beneﬁt and harm in light of our ﬁndings 
regarding pharmacological treatments, and we agree with 
these comments. The most startling ﬁnding regarding 
pharmacological treatments for neck pain was the lack of 
quality trials of medication for neck pain. The ﬁnding of 
short-term beneﬁt for orphenadrine/paracetamol, needs 
consideration in the context of lack of evidence about long 
term beneﬁt and potential harms.
Andrew M Leaver, Kathryn M Refshauge, Christopher 
G Maher and James H McAuley
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